Skip to main content
Hana Pharm. Co., Ltd. logo

Hana Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 293480 ISIN · KR7293480000 KO Manufacturing
Open in API
Filings indexed 243 across all filing types
Latest filing 2025-02-28 Remuneration Information
Country KR South Korea
Listing KO 293480

About Hana Pharm. Co., Ltd.

http://www.hanaph.co.kr/eng/index.do

Hana Pharm. Co., Ltd. is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of medical products. The company specializes in anesthetics and narcotic analgesics, establishing a strong position in these therapeutic areas. Its portfolio also encompasses generic drugs, active pharmaceutical ingredients (APIs), antiemetics, and antibiotics. Focused on innovation, Hana Pharm's research and development pipeline includes novel drugs targeting the nervous system. Key projects under development are Byfavo Inj. (remimazolam), an ultra-short-acting anesthetic and sedative, and a new multi-functional MRI contrast agent. The company serves a global market and is expanding its capacity for injectable medicines to meet growing demand.

Recent filings

Filing Released Lang Actions
기타경영사항(자율공시)
Remuneration Information Classification · 100% confidence The document is a regulatory disclosure (자율공시) from Hana Pharm regarding the introduction of a Restricted Stock Unit (RSU) program and the planned distribution of treasury shares to employees. Since this involves the company's capital structure and the allocation of its own shares for compensation, it falls under the category of share-related capital changes or corporate actions. Given the specific nature of the announcement regarding the use of treasury shares for RSU, 'SHA' (Share Issue/Capital Change) is the most appropriate classification.
2025-02-28 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Hana Pharm. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation material provided to shareholders to inform them of the meeting and request their participation/votes, fitting the definition of a Proxy Solicitation & Information Statement.
2025-02-21 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Hana Pharm regarding a decision on cash dividends. It specifies the dividend amount per share, the total dividend amount, the dividend record date, and the date of the upcoming general meeting of shareholders to approve the dividend. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2025-02-21 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement from Hana Pharm regarding the setting of a record date and shareholder register closure period for their upcoming Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal regulatory notice of the procedural steps for the meeting. Given it is a standard regulatory disclosure regarding corporate actions, it fits best under the RNS category.
2024-12-11 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory filing from Hana Pharm regarding the determination of a record date for shareholder registry closure for the purpose of cash/in-kind dividends. It explicitly states that this is not the final dividend declaration, but a procedural step to set the record date for potential future dividends. Since it pertains to dividend-related shareholder rights and record dates, it falls under the category of dividend-related announcements.
2024-12-11 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Hana Pharm Co., Ltd., covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial and operational information, including company overview, business activities, production data, and management details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.